Epidemiological trends in invasive candidiasis: Results from a 15-year study in Sousse region, Tunisia

Journal de Mycologie Medicale

Volumn 21, Issue 2, 2011, Pages 123-129

  Saghrouni, F ^a   Bougmiza, I ^b   Ben Abdeljelil, J ^a   Yacoub, A ^a   Khammari, I ^a   Fathallah, A ^a   Mtiraoui, A ^b   Ben Said M ^b  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b UNIVERSITY OF SOUSSE   (Tunisia)

Author keywords

Candida spp.; Epidemiology; Invasive candidiasis; Tunisia

Indexed keywords

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; EPIDEMIOLOGICAL DATA; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; INCIDENCE; INTRAVASCULAR CATHETER; INVASIVE CANDIDIASIS; LABORATORY TEST; MAJOR CLINICAL STUDY; NEONATOLOGY; NONHUMAN; SPECIES DISTRIBUTION; TREND STUDY; TUNISIA;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 79958852945     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2011.04.004     Document Type: Article

References (29)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128.
2. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schønheyder H.C., Knudsen J.D., Jensen I.M., et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and number of isolates with reduced azole susceptibility. J Clin Microbiol 2005, 43:4434-4440.
3. Ásmundsdóttir L.R., Erlendsdóttir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year Nationwide Study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
4. Chow J.K., Golan Y., Ruthazer R., Karchmer A.W., Carmeli Y., Lichtenberg D., et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the Intensive Care Unit. Clin Infect Dis 2008, 46:1206-1213.
5. Clemons K.V., Feroze F., Holmber K., Stevens D.A. Comparative analysis of genetic variability among Candida albicans isolates from different geographic locales by three genotypic methods. J Clin Microbiol 1997, 35:1332-1336.
6. Colombo A.L., Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003, 22:470-474.
7. Conde-Rosa A., Amador R., Pérez-Torres D., Colón E., Sánchez-Rivera C., Nieves-Plaza M., et al. Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center. P R Health Sci J 2010, 29:26-29.
8. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702.
9. Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006, 25:419-425.
10. Falagas M.E., Roussos N., Vardakas K.Z. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010, 14:954-966.
11. Girão E., Levin A.S., Basso M., Gobara S., Gomes L.B., Medeiros E.A., et al. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian university hospital. Med Mycol 2008, 46:581-588.
12. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
13. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
14. Kalkanci A., Dizbay M., Turan O., Fidan I., Yalçin B., Hirfanoǧlu I., et al. Nosocomial transmission of Candida pelliculosa fungemia in a pediatric Intensive Care Unit and review of the literature. Turk J Pediatr 2010, 52:42-49.
15. Kontoyiannis D.P., Vaziri I., Hanna H.A., Boktour M., Thornby J., Hachem R., et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001, 33:1676-1681.
16. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., et al. Prior antimicrobial therapy and risk for hospital acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005, 49:4555-4560.
17. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
18. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33:641-647.
19. Méan M., Marchetti O., Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008, 12:204.
20. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 100:617-623.
21. Nolla-Salas J., Sitges-Serra A., León-Gil C., Martínez-González J., León-Regidor M.A., Ibáñez-Lucía P., et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997, 23:23-30.
22. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
23. Pfaller M.A., Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40:3551-3557.
24. Pfaller M.A., Diekema D.J. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10:11-23. International Fungal Surveillance Participant Group.
25. Picazo J.J., González-Romo F., Candel F.J. Candidemia in the critically ill patient. Int J Antimicrob Agents 2008, 32:83-85.
26. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006, 7:495-504.
27. Trofa D., Gácser A., Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21:606-625.
28. Van Asbeck E.C., Clemons K.V., Stevens D.A. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 2009, 35:283-309.
29. White M. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis 1997, 24:1129-1130.